采纳股份(301122) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥87,393,800.82, representing a decrease of 10.54% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,119,485.00, a decline of 104.62% year-on-year[5] - Total operating revenue for Q3 2025 was CNY 245,772,123.41, a decrease of 15.8% compared to CNY 292,116,185.53 in the same period last year[25] - Net profit for the period was CNY 7,325,822.33, a significant decline of 87.3% compared to CNY 57,452,000.48 in the previous year[26] - The company reported a decrease in gross profit margin, with operating profit dropping to CNY 8,411,563.73 from CNY 62,292,887.26 year-over-year[26] Cash Flow - The net cash flow from operating activities decreased by 60.50% to ¥33,682,759.82 year-to-date[12] - Operating cash flow for the current period is ¥33,682,759.82, a decrease of 60.5% compared to ¥85,277,615.90 in the previous period[28] - Net cash flow from financing activities is -¥28,657,310.20, an improvement from -¥49,043,263.20 in the previous period[29] - Cash inflow from financing activities totals ¥5,733,955.69, compared to ¥1,038,081.76 in the previous period[29] - The ending balance of cash and cash equivalents is ¥361,201,466.73, an increase from ¥275,633,116.58 in the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,930,383,529.43, down 2.55% from the end of the previous year[5] - Total non-current assets increased to CNY 935,596,428.31, up from CNY 846,590,930.24 year-over-year[22] - Total liabilities decreased to CNY 134,847,556.11 from CNY 166,483,138.90 in the previous year[23] - The company’s total assets were CNY 1,930,383,529.43, down from CNY 1,980,925,047.43 year-over-year[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,731[14] - The largest shareholder, Lu Jun, holds 28.29% of shares, totaling 34,580,000 shares[14] - The total number of restricted shares held by major shareholders remains unchanged at 78,000,000 shares[17] - The company has not identified any related party transactions among the top shareholders[15] Operational Challenges - The company is currently facing an FDA import warning affecting its subsidiary, Jiangsu Caina Medical Technology Co., Ltd., which may significantly impact future revenue and profits[19] - The company is actively communicating with the FDA to resolve the import warning issue but cannot predict the timeline for resolution[19] - Inventory increased by 30.60% to ¥96,536,076.93, primarily due to slow shipments influenced by overseas market conditions[9] - The company has not disclosed any new product developments or market expansions in the current report[18] Expenses - The company's management expenses rose by 55.81% to ¥37,734,189.88, mainly due to increased depreciation of new factory assets[10] - Investment income decreased by 30.53% to ¥9,623,896.44, attributed to reduced cash management returns[10] - The company reported a significant increase in tax and additional charges by 86.33% to ¥4,566,516.93, mainly due to property tax on newly added factory assets[10] - Research and development expenses were CNY 16,446,738.78, down 13.4% from CNY 18,993,814.45 in the previous year[25]